Table 2.
GnRH Agonists Approved for the Treatment of Advanced Prostate Cancer
| Generic Names | Trade | Dose (mg) | Route of Administration | Dosing Interval (days) |
|---|---|---|---|---|
| Leuprolide acetate for | Lupron depot* | 7.5 | IM | 28 |
| depot suspension | Lupron depot | 22.5 | IM | 84 |
| Lupron depot | 30 | IM | 112 | |
| Goserelin acetate | Zoladex† | 3.6 | SC | 28 |
| implant | Zoladex | 10.8 | SC | 84 |
| Triptorelin pamoate | Trelstar depot‡ | 3.75 | IM | 28 |
| injectable suspension | Trelstar LA‡ | 11.25 | IM | 84 |
| Leuprolide acetate for | Eligard§ | 7.5 | SC | 28 |
| injectable suspension | Eligard | 22.5 | SC | 84 |
| Eligard | 30 | SC | 112 | |
| Leuprolide acetate | Viadur∥ | 65 | SC | 365 |
| implant | ||||
| Histrelin acetate implant | Vantas¶ | 50 | SC | 365 |
*
Abbott Laboratories, Abbott Park, IL.
†
AstraZeneca Pharmaceuticals, Wilmington, DE.
‡
Watson Pharmaceuticals, Corona, CA.
§
Sanofi-Synthelabo, New York, NY.
∥
ALZA Corp., Mountain View, CA.
¶
Valera Pharmaceuticals, Cranbury, NJ.
GnRH, gonadotropin-releasing hormone; IM, intramuscularly; SC, subcutaneously.